Repligen Corporation (RGEN) Receives Consensus Rating of “Buy” from Brokerages
Shares of Repligen Corporation (NASDAQ:RGEN) have been given an average rating of “Buy” by the eight analysts that are covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $41.00.
RGEN has been the subject of a number of research reports. Janney Montgomery Scott lifted their price target on Repligen Corporation from $42.00 to $47.00 in a research note on Friday, June 23rd. BidaskClub upgraded Repligen Corporation from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 24th. William Blair initiated coverage on Repligen Corporation in a research note on Friday, July 21st. They issued an “outperform” rating for the company. Jefferies Group LLC reiterated a “hold” rating and issued a $40.00 price target (up from $33.00) on shares of Repligen Corporation in a research note on Wednesday, June 28th. Finally, Zacks Investment Research upgraded Repligen Corporation from a “hold” rating to a “buy” rating and set a $42.00 price target for the company in a research note on Wednesday, June 14th.
Large investors have recently bought and sold shares of the stock. Quantbot Technologies LP bought a new position in Repligen Corporation in the second quarter worth about $120,000. Ameritas Investment Partners Inc. bought a new position in Repligen Corporation in the first quarter worth about $103,000. Oppenheimer Asset Management Inc. bought a new position in Repligen Corporation in the second quarter worth about $123,000. Victory Capital Management Inc. lifted its holdings in Repligen Corporation by 76.6% in the first quarter. Victory Capital Management Inc. now owns 3,400 shares of the biotechnology company’s stock worth $120,000 after acquiring an additional 1,475 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Repligen Corporation by 31.9% in the first quarter. JPMorgan Chase & Co. now owns 3,755 shares of the biotechnology company’s stock worth $133,000 after acquiring an additional 908 shares during the last quarter. Institutional investors and hedge funds own 97.91% of the company’s stock.
Shares of Repligen Corporation (NASDAQ RGEN) opened at 43.76 on Friday. Repligen Corporation has a one year low of $26.16 and a one year high of $46.81. The stock has a market capitalization of $1.63 billion, a P/E ratio of 85.64 and a beta of 1.21. The firm’s 50-day moving average price is $42.29 and its 200-day moving average price is $39.00.
Repligen Corporation (NASDAQ:RGEN) last announced its earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.05. The company had revenue of $32.40 million during the quarter, compared to the consensus estimate of $31.72 million. Repligen Corporation had a return on equity of 9.90% and a net margin of 15.61%. The company’s revenue was up 11.0% on a year-over-year basis. During the same period last year, the firm earned $0.16 earnings per share. Equities research analysts anticipate that Repligen Corporation will post $0.59 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/09/24/repligen-corporation-rgen-receives-consensus-rating-of-buy-from-brokerages.html.
About Repligen Corporation
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.